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Background: Low plasma triiodothyronine (T3) levels are considered a prognostic predictor of death in
heart failure (HF) patients.
Aim: To study an association between plasma T3 levels and several cardiac, neurohormonal, and
metabolic markers of HF.
Methods: A total of 133 ambulatory HF patients (114 males; mean age 63.2 years) with left ventricular
ejection fraction !40% were enrolled. TSH, total tetraiodothyronine (T4) and T3, N-terminal pro-brain
natriuretic peptide (NT-proBNP), and other cardiac and metabolic parameters were measured. The
lowest tertile of T3 (group 1) was compared against the two upper ones (group 2).
Results: In simple logistic regression, the lowest T3 tertile was associated with more advanced HF
disease status: older (age: odds ratio (OR)Z1.05; confidence interval (CI) 95% 1.01–1.09, PZ0.004),
lower functional capacity (walking test: ORZ0.996; CI 95% 0.993–0.999, PZ0.008), higher
NT-proBNP (ORZ1.64; CI 95% 1.19–2.27, PZ0.003) and adiponectin levels (ORZ1.07; CI 95%
1.02–1.11, PZ0.004), lower DHEAS log-transformed (ORZ0.50; CI 95% 0.31–0.80, PZ0.004),
and the presence of lower phase angle values as measured by body bioelectrical impedance analysis
(ORZ3.18; CI 95% 1.50–6.71, PZ0.04) and worse renal function (ORZ0.96; CI 95% 0.94–0.98,
PZ0.003). T3 levels in the lowest tertile were independently associated with low phase angle values
(ORZ2.95, CI 95% 1.16–7.50, PZ0.02) and the log transformation of DHEAS (ORZ0.56; CI 95%
0.32–0.97, PZ0.04).
Conclusion: We have demonstrated an association between plasma T3 levels in the lower range and
other deranged hormonal and metabolic parameters in HF patients.
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Euthyroid sick syndrome and non-thyroidal illness
syndrome are the terms currently used to define a
condition characterized by an impairment of the
hypothalamus–pituitary–thyroid axis present in most
critically ill patients. A fall in serum triiodothyronine
(T3), also known as low T3 syndrome, is one of the most
common changes observed (1–3). This pathological
process has been found to be present in about 30%
of congestive heart failure (HF) patients. Those
patients classified as New York Heart Association
(NYHA) functional class III–IV (4) have shown a
higher prevalence of low T3 levels. Furthermore, the
low T3 syndrome in HF is considered a predictor of
death (5, 6).ndocrinologySeveral changes consistent with the downregulation
of the thyroid hormone signaling system take place
in the advanced failing heart and postinfarcted
myocardium. This hypothyroid phenotype includes a
lower expression of thyroid hormone receptor-a1 (TRa1
or THRA), sarcoplasmic reticulum calcium ATPase
(SERCA2 or ATP2A2), and higher expression of b
myosin genes (7–9). Although these changes in cardiac
phenotype might be due to low circulating levels of
thyroid hormones in HF, impaired thyroid hormone
signaling might also result from the re-expression of
deiodinase type 3 (D3), the local thyroid hormone
inactivating enzyme, in cardiomyocytes (10, 11).
Reversal of this hypothyroid phenotype with physio-
logical replacement of T3 might prove beneficial as been
shown in animal models of HF where left ventricularDOI: 10.1530/EJE-11-0094
Online version via www.eje-online.org
938 G Brenta and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011) 164contractile performance was improved (12) or with
ventricular ischemia where early long-term L-T3
replacement has been shown to preserve the mito-
chondria and prevent ischemic cardiac remodeling (13).
Moreover, studies of short-term T3 replacement in
patients undergoing coronary artery bypass surgery
and in patients with advanced HF have also demonstrated
a hemodynamic benefit with such therapy (14–16).
It can be argued that low T3 levels present in HF
might not just indicate disease progression but they
might have a pathophysiological role. This might be
explained by the direct effects of low T3 levels in the
cardiovascular system and/or through a possible
interaction with catabolic and inflammatory par-
ameters also present in HF (17). This is in line with
the idea that the pathophysiological phenomenon
behind HF initially involves a compensatory activation
of hormonal, immunological, and proinflammatory
systems. However, a later phase ensues where all of
these compensatory responses eventually become
maladaptive (18). The use of markers such as brain
natriuretic peptide (BNP) (19) or adiponectin (20),
which provide prognostic information of adverse out-
come in HF, is well established. However, an interaction
between T3 levels and catabolic parameters present in
HF still remains a matter of interest for further research.
In this study, we explored a possible association of low
T3 circulating levels with some of the hemodynamic,
neurohormonal, and metabolic prognostic parameters
present in congestive HF patients.Materials and methods
Subjects
We prospectively included 151 consecutive ambulatory
patients with systolic HF referred to our institute between
May 2005 and March 2007 in the MIMICA study,
designed to explain the relationship between metabolic
and inflammatory markers and severity of disease (21).
All patients had left ventricular ejection fraction (LVEF)
%40% and were in a stable condition (not hospitalized
because of decompensated HF, nor required a visit to
emergency department or a raise of the diuretic dose)
at least for 3 months prior to their inclusion in the study.
After excluding overt hypothyroid and hyperthyroid
patients, 133 patients remained to be included in the
present analysis. Overt hypothyroidism was defined as
TSH valuesO5.0 mIU/ml andtotal tetraiodothyronine (T4)
values !4.5 mg/dl. Overt hyperthyroidism was defined
as TSH values !0.3 mIU/ml and T4 values O13 mg/dl.Blood sampling and analysis
Following a 12 h overnight fast, venous blood was
obtained from the antecubital vein. Hematological
parameters, urea, creatinine, glycemia, baseline insulin,www.eje-online.orgliver, and cholesterol panels were determined. We
measured high-sensitivity C-reactive protein (hsCRP),
uric acid, leptin, adiponectin, albumin, cortisol and
DHEAS, and N-terminal pro-BNP (NT-proBNP).
For determination of hsCRP, leptin, adiponectin,
NT-proBNP, cortisol, and DHEAS, all the samples were
processed in the same assay.
hsCRP was determined by Tina-quant CRP (Latex,
Mannheim, Germany) high-sensitive immunoturbidi-
metric assay (Roche Diagnostics) in a Hitachi 917
autoanalyzer. The intra assay coefficient of variation
(CV) was 0.43%.
Leptin was measured by IRMA (Active Human Leptin
IRMA, Diagnostic System Laboratories, Inc., Webster,
TX, USA). The intra assay CV of the assay at 3.0 ng/ml
was 3.9% and at 12 ng/ml was 1.7%.
Adiponectin was determined by enzyme immunoas-
say (Quantikine Human Adiponectin/Acrp30 Immu-
noassay. R&D Systems, Inc., Minneapolis, MN, USA).
The intra assay CV of the assay at 19.8 mg/ml was 2.5%.
NT-proBNP was determined by immunoassay
(proBNP Elecsys Roche Diagnostics GmbH). The intra
assay CV was 2.7%.
Plasmatic and urinary cortisol levels were evaluated
by immunoassay (Access Cortisol, Beckman Coulter,
Fullerton, CA, USA). The intra assay CV was 6.4% for
plasmatic and 4% for urinary-free cortisol.
DHEAS was assessed by RIA (Coat-A-Count DHEAS-
SO4 Diagnostic Products Corporation, Los Angelas, CA,
USA). The intra assay CV was below 5.3%.
TSH, T3, and T4 were determined by electrochemilu-
minescence immunoassay (Elecsys 1010-ROCHE Diag-
nostic). TSH reference values were 0.3–5.0 mIU/ml.
Intra assay CV% was 2% and inter assay CV was 3.7%
using a human serum sample with 0.9 mIU/ml (EP5-
Modified protocol of National Committee of Clinical
Laboratories Standards, NCCLS). Analytical sensitivity
of the method was: 0.005 and functional sensitivity was
0.014 mIU/ml.
T4 reference values were 4.5–13.0 mg/dl. Intra assay
CV% was 2.9% and inter assay CV was 3.9% using a
human serum sample with 9.0 mg/dl in six daily assays
during 10 days (EP5-A, NCCLS).
T3 reference values were 0.8–2.0 ng/ml. Intra assay
CV% was 4.1% and inter assay CV was 4.9% using a
human serum sample with 2.1 ng/ml in six daily assays
during 10 days (EP5-A, NCCLS). Analytical sensitivity
was 0.195 ng/ml.
In non-diabetic patients, insulin resistance was
calculated by the homeostasis model assessment index
for insulin resistance (HOMA-IR)Z(fasting plasma
glucose (mg/dl)!fasting plasma insulin (mIU/ml))/
(18!22.5).Echocardiography
The acquisition of echocardiographic data was perfor-
med using the Philips iE33 Ultrasound.
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from the parasternal long-axis view following the
standard Echocardiography American guidelines, deter-
mining left ventricle diastolic and systolic diameters,
interventricular septum, posterior wall, and aortic root.
Left atrial area was traced in apical four-chamber view.
Ventricular function was performed in four-chamber
apical view: the endocardial border was manually
traced in end systole and end diastole and using the
Simpson method (biplane), left ventricular end diastolic
volume, left ventricular end systolic volume, and
ejection fraction were assessed.Six minutes walking test
Functional capacity was assessed with the 6 min
walking test, performed in a flat straight 30 m corridor.
The test was conducted under the control of an
experienced physician who encouraged the patients to
walk in the corridor at a higher rate from one extremity
to the other as much time as possible. Patients were
allowed to stop if necessary but were urged to resume the
walk as soon as they recovered. Baseline and final heart
rate and systolic blood pressure were recorded. The
distance walked in 6 min (6MWD) is expressed in meters.Table 1 Comparison of demographic parameters, clinical charac-
teristics, heart failure disease status, and use of drugs between





Male sex (%) 88.8 81.8 0.29
Age (years) 67.2G11.6 60.9G11.8 0.002
Diabetes (%) 28.9 23.8 0.53
Hypertension (%) 46.6 55.6 0.32
Ischemic etiology (%) 62.2 48.8 0.14
NYHA III–IV (%) 35.5 22.7 0.11
Atrial fibrillation (%) 15.5% 6.8% 0.11
b-Blockers (%) 95.5% 89.8% 0.25
ACEI–ARB (%) 73.3% 85.2% 0.10
Amiodarone (%) 46.6% 31.8% 0.09
Diuretics (%) 93.3% 75% 0.01
Digitalis (%) 28.8% 19.3% 0.21
LVEF 28.2G7.8 28.4G7.7 0.90
6 min walking test (mts) 251G132 320G136 0.006Bioelectrical impedance analysis
In every patient, body composition (muscle mass, fat
mass content, and total, intra- and extracellular water)
was assessed by body bioelectrical impedance analysis
(BIA). All the tests were performed by the same skilled
physician using a tetrapolar and multiple frequency
equipment (four-channel bioimpedance meter BioScan
MSR-916, Maltron International Ltd, Rayleigh, UK).
BIA has been validated as a suitable method to
determine body composition and is well correlated
with dual-energy X-ray absorptiometry (22). The
method is based on the resistance encountered through
water and the body tissues during low-intensity electric
current passage. The two electrodes are placed on the
palm and wrist as well as the other two electrodes on
the foot sole and ankle; all electrodes are placed on the
right side of the body. In order to perform the test, the
patient has to remain lying down on the supine
position, in a fasted condition for the last 6 h and
having avoided strenuous exercise within the last 12 h.
Determination of phase angle, a marker of membrane
damage, was also assessed (22). Low phase angle, a
marker of membrane damage, was defined as !5.5
degrees in women or !6.5 degrees in men.Resting metabolic rate (kcal) 1416G208 1487G244 0.09
Fat-free mass (%) 70.6G7.4% 68.9G7.9 0.22
Phase angle (degrees) 6.5G2.2 7.2G2.1 0.08
Low phase angle (%) 62.2 34.1 0.002
BMI, body mass index; NYHA III–IV, New York Heart Association functional
class III–IV; ACEI, angiotensin-converting enzyme inhibitor; ARB, angioten-
sin receptor blocker; LVEF, left ventricular ejection fraction.Protocol
All tests were carried out within 5 days of inclusion,
at the Instituto Cardiovascular de Buenos Aires.
The investigation complied with the principles outlinedin the Declaration of Helsinki. The protocol was approved
by the institutional ethics committee and signed
informed consent was obtained from each participant.
In order to explore the relationship between low T3
values and the baseline parameters, the population was
divided into tertiles of T3, and the lowest tertile (group
1) was compared against the two upper ones (group 2).Statistical analysis
Categorical variables are presented as percentages and
continuous variables as meanGS.D. when their distri-
bution was normal, or median and interquartile range
when it was not.
Comparisons between the two groups were performed
by Student’s t-test (continuous variables) or c2 test
(categorical variables). Simple and multiple logistic
regressions were performed to define variables signi-
ficantly associated with the lowest tertile of T3.
Logarithmic transformation was performed to achieve
a normal distribution for skewed variables and to
introduce them in the multivariable analysis.
Statistical analysis was performed with Stata 10
package (StataCorp, College Station, TX, USA).Results
Baseline characteristics
Of the 133 patients, 114 (85.7%) were males and mean
age was 63.2G11.5 years; 9.7% were cigarette
smokers, 24.8% diabetic, 54.9% had arterialwww.eje-online.org








Hemoglobin (g/dl) 13.8G1.5 14.1G1.5 0.26




Na (meq/l) 140G4 141G3 0.16
K (meq/l) 4.7G0.4 4.7G0.4 0.63
HOMA-IR 2.3G1.5 3.1G2.5 0.09
Cholesterol (mg/dl) 188G41 199G60 0.32
Leptin (ng/ml) 9.5G6.8 9.7G6.1 0.86
Cortisol (mg/dl) 16.9G4.9 16.1G4.8 0.30
DHEAS (mg/dl) 40 (24–70) 63 (40–99) 0.003
hsCRP (mg/l) 2.7 (1.3–5.4) 2.7 (1.3–5.7) 0.96
NT-proBNP (pg/ml) 1350 (956–2676) 794 (235–1703) 0.0004
Adiponectin (mg/ml) 16.8G7.4 12.3G7.9 0.002
T3 (ng/ml) 0.83G0.07 1.14G0.16 0.0001
T4 (mg/dl) 8.6G1.8 7.9G1.3 0.028
TSH (mIU/ml) 2.6G2.3 3.3G2.5 0.12
GFR, glomerular filtration rate; WBC, white blood cell; HOMA-IR, homeostasis
model assessment index for insulin resistance; hsCRP, high-sensitivity
C-reactive protein; NT-proBNP, N-terminal pro-brain natriuretic peptide; T3,
triiodothyronine; T4, total tetraiodothyronine.
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previous myocardial infarction, and 27.1% were
classified as functional class NYHA III–IV. Mean LVEF
was 28.3G7.9% and mean 6 min walking distance was
293G140 mts. The vast majority of the patients used
b-blockers (90.2%) and angiotensin-converting enzyme
inhibitor (ACEI) and an angiotensin receptor blocker
(ARB), ACEI–ARB (80.4%). Approximately one-third of
our patients (36.8%) were on amiodarone.
T3 values ranged from 0.57 to 1.68 ng/ml. Mean T3
value was 1.03G0.20 ng/ml.Comparison of groups
The cutoff point between groups 1 and 2 was
0.95 ng/ml.
Tables 1 and 2 show the comparison of measured
parameters between groups. Group 1 patients (low T3
values) were significantly older, with higher use ofTable 3 Variables significantly associated with the lower
Simple logistic reg
Variables OR CI 95%
Age (years) 1.05 1.01–1.09
Functional class III–IV 1.87 0.85–4.12
Amiodarone use 1.87 0.89–3.92
6 min walking test (mts) 0.996 0.993–0.999
GFR (ml/min/1.73 m2) 0.96 0.94–0.98
DHEAS log value 0.50 0.31–0.80
NT-proBNP log value 1.64 1.19–2.27
Adiponectin (mg/ml) 1.07 1.02–1.11
Low phase angle 3.18 1.51–6.72
CI, confidence interval; OR, odds ratio; GFR, glomerular filtration
www.eje-online.orgdiuretics, and a trend to be more symptomatic and more
frequently treated with amiodarone. They presented
with less than 6 min walking distance, worse renal
function, lower levels of DHEAS, and higher NT-proBNP
and adiponectin values. Their phase angle was lower,
and the prevalence of low phase angle was higher. LVEF,
left ventricular diameters and volumes, and E/A relation
were not significantly different among tertiles.
In simple logistic regression (Table 3), the lowest T3
tertile was associated with more advanced HF disease
status: older, lower functional capacity, higher
NT-proBNP and adiponectin levels, lower DHEAS log-
transformed, and the presence of low phase angle values
and worse renal function.
In multiple logistic regression (Table 3), the lowest
tertile of T3 was independently associated with low
phase angle values (odds ratio (OR)Z2.95, confidence
interval (CI) 95% 1.16–7.50, PZ0.02) and the
log transformation of DHEAS (ORZ0.58; CI 95%
0.37–0.92, PZ0.022).Discussion
In this study, we have shown for the first time that low
T3 levels, a strong indicator of poor prognosis in HF, are
associated with lower BIA phase angle (a marker of
membrane damage) and lower DHEAS (expression of
diminished anabolic status). The association was
independent of the influence of other recognized
markers of HF such as age, weight loss, renal function,
or muscle mass.
NT-proBNP also appeared related to lower T3 levels,
with significantly higher levels in group 1 patients.
NT-proBNP levels are used for screening, diagnosis of
acute HF, and to establish prognosis in HF. Higher levels
imply a worse outcome (23). It has previously been
shown that free T3 is significantly related to NT-proBNP
in patients with cardiovascular disease. Moreover, both
parameters exert an independent and additively prog-
nostic value for mortality in HF (24, 25). In agreement
with these studies, as previously mentioned, we alsoT3 tertile in univariate and multiple logistic regressions.
ression Multiple logistic regression
P OR CI 95% P
0.004 0.98 0.93–1.03 0.51
0.11 1.29 0.50–3.28 0.59
0.09 1.65 0.68–3.98 0.26
0.008 0.999 0.995–1.003 0.72
0.003 0.97 0.95–1.00 0.15
0.004 0.56 0.32–0.97 0.04
0.003 1.09 0.72–1.64 0.68
0.004 1.03 0.97–1.09 0.26
0.002 2.95 1.16–7.50 0.02
rate; NT-proBNP, N-terminal pro-brain natriuretic peptide.
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levels of T3.
A novel association between low T3 levels in HF and
the adrenal steroid DHEAS was revealed in this study.
It has previously been reported that plasma levels of
DHEA are decreased in patients with HF (26) and that
they can be used as a prognostic marker of bad outcome
in HF (27). Although alternative explanations for the
lower levels of this anabolic hormone in HF have been
offered (28, 29), lower DHEAS levels in HF could also be
interpreted in the light of a hypothyroid state. Lower
DHEAS levels have previously been reported in
hypothyroid women (30). It has been suggested that
the lower concentrations of DHEA and DHEAS in
hypothyroidism could be explained by decreased
adrenal steroidogenesis (31). Moreover, an indirect
regulation by thyroid hormones of human DHEA
sulfotransferase family 1A member 2 (SULT2A1), the
enzyme that catalyzes sulfonation of DHEA to DHEAS
has been reported and could also be playing a role in
lower DHEAS levels described in hypothyroidism (32).
On the other hand, given that oxidative stress is present
in hypothyroid patients (33), lower DHEAS levels found
in our low T3 patients could also be explained through
a decrease in 17,20-lyase activity.
We evaluated body composition using whole-body
BIA method and found that the chances of pertaining to
the low T3 group increased nearly three times when
phase angle was low. A lower phase angle implies cell
death or decreased cell integrity (34). With regard to HF,
it has been described that bioimpedance phase angles
are lower in patients with functional class NYHA III–IV
compared with those with NYHA I–II (35). In
agreement with our findings, a smaller phase angle
after 6 months of follow-up was observed in HF patients
who developed some alteration in the thyroid profile
when compared with the rest of the cohort (36).
A limitation of our study is the high use of
amiodarone found in the low T3 group. Due to its big
iodine load, amiodarone can decrease conversion of T4
to T3 yielding low serum T3 levels. However, to discard
its possible effects as a confounder, amiodarone use,
together with other parameters such as age, that has
been also reportedly associated with lower T3 values,
was adjusted within the multivariable analysis and was
not independently related to low T3 levels. Furthermore,
our group of patients with the lowest T3 levels was in a
more advanced HF status and this is in line with authors
that reported that concomitant amiodarone therapy
does not have a relevant influence in the higher
mortality rate found in HF patients with low T3 (37).
On the other hand, the strengths of this study lie on
the multiplicity of metabolic and neurohormonal
parameters included. The reported findings are original
and should be considered hypothesis generating.
In conclusion, we have found that low T3 levels in HF
patients are associated with several markers of illness.
Lower anabolic activity and more severe membranedamage could partially explain a more advanced HF
status among patients with low T3 levels.Declaration of interest
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